The prolactin receptor as a therapeutic target in human diseases: browsing new potential indications

Prolactin (PRL) signaling has emerged as a relevant target in breast and prostate cancers. This has encouraged various laboratories to develop compounds targeting the PRL receptor (PRLR). As the latter is widely distributed, it is timely to address whether other conditions could also benefit from such inhibitors.The authors briefly overview the two classes of PRLR blockers, which involve: i) PRL-core based analogs that have been validated as...